Table 1.
Clinical Characteristics of Patients According to CSN2 in the Training and Validation Cohorts
| Variables | Training Cohort (n = 267) |
Validation Cohort (n =238) |
||||||
|---|---|---|---|---|---|---|---|---|
| N | Low CSN2 (%) | High CSN2(%) | P Value | N | Low CSN2 (%) | High CSN2 (%) | P Value | |
| Gender | 0.497 | 0.354 | ||||||
| Male | 166 | 80(48.2%) | 86(51.8%) | 143 | 75(52.4%) | 68(47.6%) | ||
| Female | 101 | 53(52.5%) | 48(47.5%) | 95 | 44(46.3%) | 51(53.7%) | ||
| Age(years) | 0.425 | 0.697 | ||||||
| <60 | 138 | 72(52.2%) | 66(47.8%) | 117 | 60(51.3%) | 57(48.7%) | ||
| ≧60 | 129 | 61(47.3%) | 68(52.7%) | 121 | 59(48.8%) | 62(51.2%) | ||
| Tumor location | 0.299 | 0.357 | ||||||
| Colon | 120 | 64(53.3%) | 56(46.7%) | 99 | 53(53.5%) | 46(46.5%) | ||
| Rectum | 147 | 69(46.9%) | 78(53.1%) | 139 | 66(47.5%) | 73(52.5%) | ||
| Differentiation status | 0.99 | 0.164 | ||||||
| Well | 66 | 33(50%) | 33(50%) | 53 | 22(41.5%) | 31(58.5%) | ||
| Moderate | 160 | 80(50%) | 80(50%) | 137 | 68(49.6%) | 69(50.4%) | ||
| Poor and undifferentiated | 41 | 20(48.8%) | 21(51.2%) | 48 | 29(60.4%) | 19(39.6%) | ||
| CEA | 0.08 | 0.167 | ||||||
| Elevated | 85 | 49(57.6%) | 36(42.4%) | 78 | 44(56.4%) | 34(43.6%) | ||
| Normal | 182 | 84(46.2%) | 98(53.8%) | 160 | 75(46.9%) | 85(53.1%) | ||
| CA199 | 0.094 | 0.325 | ||||||
| Elevated | 44 | 27(61.4%) | 17(38.6%) | 46 | 26(56.5%) | 20(43.5%) | ||
| Nomal | 223 | 106(47.5%) | 117(52.5%) | 192 | 93(48.4%) | 99(51.6%) | ||
| Depth of invasion | 0.009 | 0.323 | ||||||
| T1 | 10 | 2(20%) | 8(80%) | 14 | 4(28.6%) | 10(71.4%) | ||
| T2 | 37 | 14(37.8%) | 23(62.2%) | 41 | 18(43.9%) | 23(56.1%) | ||
| T3 | 166 | 80(48.2%) | 86(51.8%) | 108 | 57(52.8%) | 51(47.2%) | ||
| T4a | 18 | 12(66.7%) | 6(33.3%) | 26 | 12(46.2%) | 14(53.8%) | ||
| T4b | 36 | 25(69.4%) | 11(30.6%) | 49 | 28(57.1%) | 21(42.9%) | ||
| Lymph node metastasis | 0.003 | 0.001 | ||||||
| N0 | 159 | 66(41.5%) | 93(58.5%) | 116 | 44(37.9%) | 72(62.1%) | ||
| N1 | 74 | 44(59.5%) | 30(40.5%) | 77 | 46(59.7%) | 31(40.3%) | ||
| N2 | 34 | 23(67.6%) | 11(32.4%) | 45 | 29(64.4%) | 16(35.6%) | ||
| Metastasis | 0.015 | 0.011 | ||||||
| M0 | 234 | 110(47.0%) | 124(53.0%) | 195 | 90(46.2%) | 105(53.8%) | ||
| M1 | 33 | 23(69.7%) | 10(30.3%) | 43 | 29(67.4%) | 14(32.6%) | ||
| TNM stage | 0.001 | 0.001 | ||||||
| I | 38 | 12(31.6%) | 26(68.4%) | 43 | 13(30.2%) | 30(69.8%) | ||
| II | 112 | 48(42.9%) | 64(57.1%) | 63 | 26(41.3%) | 37(58.7%) | ||
| III | 84 | 50(59.5%) | 34(40.5%) | 89 | 51(57.3%) | 38(42.7%) | ||
| IV | 33 | 23(69.7%) | 10(30.3%) | 43 | 29(67.4%) | 14(32.6%) | ||
| CD8+ cells/field (mean±S.D.) | 74.7±59.3 | 95.0±58.4 | 0.005 | 75.8±46.1 | 95.1±54.1 | 0.003 | ||
| CD8 | <0.001 | 0.028 | ||||||
| low | 133 | 81(60.9%) | 52(39.1%) | 119 | 68(57.1%) | 51(42.9%) | ||
| high | 134 | 52(38.8%) | 82(61.2%) | 119 | 51(42.9%) | 68(57.1%) | ||
| MMR | <0.001 | 0.23 | ||||||
| dMMR | 45 | 9(20%) | 36(80%) | 41 | 17(41.5%) | 24(58.5%) | ||
| pMMR | 222 | 124(55.9%) | 98(44.1%) | 197 | 102(51.8%) | 95(48.2%) | ||